CureVac and its larger rival will use messenger RNA techniques, similar to those used by Pfizer (PFE) - Get Report and Moderna (MRNA) - Get Report, to deveop a multi-variant vaccine candidate that the pair hope will be available next year.
GlaxoSmithKline, which took a 10% stake in CureVac last year, also said it would support the manufacturing of CureVac's first messenger-RNA vaccine, known as CVnCoV, which the drugmaker said in November triggered antibody development in 250 human volunteers between the ages of 18 and 60 on a level similar to that of patients recovering from COVID-19.
"We are very pleased to build on our existing relationship with GSK with a new agreement to jointly develop next generation mRNA-based vaccines, in addition to our current candidate CVnCoV," said CureVac CEO Franz-Werner Haas. "With the help of GSK's proven vaccine expertise, we are equipping ourselves to tackle future health challenges with novel vaccines."
CureVac's U.S.-listed shares, which trade on the Nasdaq, were marked 8.3% higher in early dealing Wednesday to change hands at $106.45 each. The shares were trading under $2 in early August.
GlaxoSmithKline shares, meanwhile, slumped 5% to $35.70 each after it cautioned that 2021 earnings would fall by as much as a high-digit percentage from last year as the coronavirus pandemic disruption to its traditional vaccines business -- the largest in the world -- continues to hit sales.
Last month, CureVac reached a collaboration and services agreement with pharma giant Bayer AG (BAYRY) - Get Report to accelerate the development of its vaccine program, focusing on areas such as clinical operations, regulatory affairs an supply chains.